Hyperoncotic colloids and acute kidney injury: A meta-analysis of randomized trials

Critical Care

Volumn 14, Issue 5, 2010, Pages

  Wiedermann, Christian J ^a   Dunzendorfer, Stefan ^b   Gaioni, Luigi U ^a   Zaraca, Francesco ^a   Joannidis, Michael ^b  

^a CENTRAL HOSPITAL OF BOLZANO   (Italy)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; STARCH; ALBUMINOID; HETASTARCH; HYPERONCOTIC ALBUMIN;

ACUTE KIDNEY FAILURE; ARTICLE; ASCITES; BACTERIAL PERITONITIS; CLINICAL TRIAL; COLLOID; DEATH; HUMAN; INCIDENCE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; SEPSIS; CHEMICALLY INDUCED DISORDER; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACUTE KIDNEY INJURY; ALBUMINS; COLLOIDS; HETASTARCH; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77958592046     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9308     Document Type: Article

References (60)

1. Davidson IJ. Renal impact of fluid management with colloids: a comparative review. Eur J Anaesthesiol 2006, 23:721-738. 10.1017/S0265021506000639, 16723059.
2. Dart AB, Mutter TC, Ruth CA, Taback SP. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev 2010, 1:CD007594.
3. Zarychanski R, Turgeon AF, Fergusson DA, Cook DJ, Hébert P, Bagshaw SM, Monsour D, McIntyre L. Renal outcomes and mortality following hydroxyethyl starch resuscitation of critically ill patients: systematic review and meta-analysis of randomized trials. Open Med 2009, 3:196-209.
4. Joannidis M, Druml W, Forni LG, Groeneveld AB, Honore P, Oudemans-van Straaten HM, Ronco C, Schetz MR, Woittiez AJ. Prevention of acute kidney injury and protection of renal function in the intensive care unit Expert opinion of the working group for nephrology, ESICM. Intensive Care Med 2010, 36:392-411. 10.1007/s00134-009-1678-y, 19921152.
5. Schortgen F, Girou E, Deye N, Brochard L. The risk associated with hyperoncotic colloids in patients with shock. Intensive Care Med 2008, 34:2157-2168. 10.1007/s00134-008-1225-2, 18685828.
6. Baylis C, Ichikawa I, Willis WT, Wilson CB, Brenner BM. Dynamics of glomerular ultrafiltration. IX. Effects of plasma protein concentration. Am J Physiol 1977, 232:F58-71.
7. Hiippala S, Linko K, Myllyla G, Lalla M, Makelainen A. Albumin, HES 120 and dextran 70 as adjuvants to red blood cell concentrates: a study on colloid osmotic pressure changes in vitro. Acta Anaesthesiol Scand 1991, 35:654-659. 10.1111/j.1399-6576.1991.tb03367.x, 1723826.
8. Webb AR, Barclay SA, Bennett ED. In vitro colloid osmotic pressure of commonly used plasma expanders and substitutes: a study of the diffusibility of colloid molecules. Intensive Care Med 1989, 15:116-120. 10.1007/BF00295988, 2715499.
9. Tønnessen T, Tølløfsrud S, Kongsgaard UE, Noddeland H. Colloid osmotic pressure of plasma replacement fluids. Acta Anaesthesiol Scand 1993, 37:424-426. 10.1111/j.1399-6576.1993.tb03741.x, 7686710.
10. Hiippala S, Linko K, Myllyla G, Lalla M, Hekali R, Makelainen A. Replacement of major surgical blood loss by hypo-oncotic or conventional plasma substitutes. Acta Anaesthesiol Scand 1995, 39:228-235. 10.1111/j.1399-6576.1995.tb04049.x, 7540789.
11. Nielsen VG, Baird MS, Brix AE, Matalon S. Extreme, progressive isovolemic hemodilution with 5% human albumin, PentaLyte, or Hextend does not cause hepatic ischemia or histologic injury in rabbits. Anesthesiology 1999, 90:1428-1435. 10.1097/00000542-199905000-00028, 10319792.
12. Cabrales P, Intaglietta M, Tsai AG. Increase plasma viscosity sustains microcirculation after resuscitation from hemorrhagic shock and continuous bleeding. Shock 2005, 23:549-555.
13. Jacob M, Chappell D, Conzen P, Wilkes MM, Becker BF, Rehm M. Small-volume resuscitation with hyperoncotic albumin: a systematic review of randomized clinical trials. Crit Care 2008, 12:R34. 10.1186/cc6812, 2447554, 18318896.
14. Janeway CA, Gibson ST, Woodruff LM, Heyl JT, Bailey OT, Newhouser LR. Chemical, clinical, and immunological studies on the products of human plasma fractionation. VII. Concentrated human serum albumin. J Clin Invest 1944, 23:465-490. 10.1172/JCI101514, 435363, 16695125.
15. Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001, 357:911-916. 10.1016/S0140-6736(00)04211-2, 11289347.
16. Cittanova ML, Leblanc I, Legendre C, Mouquet C, Riou B, Coriat P. Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 1996, 348:1620-1622. 10.1016/S0140-6736(96)07588-5, 8961992.
17. Zetterström H, Hedstrand U. Albumin treatment following major surgery. I. Effects on plasma oncotic pressure, renal function and peripheral oedema. Acta Anaesthesiol Scand 1981, 25:125-132. 10.1111/j.1399-6576.1981.tb01622.x, 7324819.
18. Ginès P, Titó L, Arroyo V, Planas R, Panés J, Viver J, Torres M, Humbert P, Rimola A, Llach J, Badalamenti S, Jiménez W, Gaya J, Rodés J. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988, 94:1493-1502.
19. London MJ, Ho JS, Triedman JK, Verrier ED, Levin J, Merrick SH, Hanley FL, Browner WS, Mangano DT. A randomized clinical trial of 10% pentastarch (low molecular weight hydroxyethyl starch) versus 5% albumin for plasma volume expansion after cardiac operations. J Thorac Cardiovasc Surg 1989, 97:785-797.
20. García-Compeán D, Villarreal JZ, Cuevas HB, Cantú DAG, Estrella M, Tamez EG, Castillo RV, Barragán RF. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver 1993, 13:233-238.
21. Dehne MG, Mühling J, Sablotzki A, Papke G, Kuntzsch U, Hempelmann G. Effect of hydroxyethyl starch solution on kidney function in surgical intensive care patients. Anasthesiol Intensivmed Notfallmed Schmerzther 1997, 32:348-354. 10.1055/s-2007-995067, 9333329.
22. Gentilini P, Casini-Raggi V, Di Fiore G, Romanelli RG, Buzzelli G, Pinzani M, La Villa G, Laffi G. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol 1999, 30:639-645. 10.1016/S0168-8278(99)80194-9, 10207805.
23. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, Castells L, Vargas V, Soriano G, Guevara M, Ginès P, Rodés J. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999, 341:403-409. 10.1056/NEJM199908053410603, 10432325.
24. Sola-Vera J, Miñana J, Ricart E, Planella M, González B, Torras X, Rodríguez J, Such J, Pascual S, Soriano G, Pérez-Mateo M, Guarner C. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003, 37:1147-1153. 10.1053/jhep.2003.50169, 12717396.
25. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008, 358:125-139. 10.1056/NEJMoa070716, 18184958.
26. McIntyre LA, Fergusson D, Cook DJ, Rankin N, Dhingra V, Granton J, Magder S, Stiell I, Taljaard M, Hebert PC. Fluid resuscitation in the management of early septic shock (FINESS): a randomized controlled feasibility trial. Can J Anaesth 2008, 55:819-826. 10.1007/BF03034053, 19050085.
27. Chen T-A, Tsao Y-C, Chen A, Lo G-H, Lin C-K, Yu H-C, Cheng L-C, Hsu P-I, Tsai W-L. Effect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis. Scand J Gastroenterol 2009, 44:619-625. 10.1080/00365520902719273, 19191184.
28. Fernández J, Monteagudo J, Bargallo X, Jiménez W, Bosch J, Arroyo V, Navasa M. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005, 42:627-634. 10.1002/hep.20829, 16108036.
29. Wiedermann CJ. Systematic review of randomized clinical trials on the use of hydroxyethyl starch for fluid management in sepsis. BMC Emerg Med 2008, 8:1-8. 10.1186/1471-227X-8-1, 2245977, 18218122.
30. Brochard L, Abroug F, Brenner M, Broccard AF, Danner RL, Ferrer M, Laghi F, Magder S, Papazian L, Pelosi P, Polderman KH. An Official ATS/ERS/ESICM/SCCM/SRLF Statement: Prevention and Management of Acute Renal Failure in the ICU Patient: an international consensus conference in intensive care medicine. Am J Respir Crit Care Med 2010, 181:1128-1155. 10.1164/rccm.200711-1664ST, 20460549.
31. Gerkens JF. Reproducible vasodilatation by platelet-activating factor in blood- and Krebs-perfused rat kidneys is albumin-dependent. Eur J Pharmacol 1990, 177:119-126. 10.1016/0014-2999(90)90261-4, 2311673.
32. Kaufmann MA, Castelli I, Pargger H, Drop LJ. Nitric oxide dose-response study in the isolated perfused rat kidney after inhibition of endothelium-derived relaxing factor synthesis: the role of serum albumin. J Pharmacol Exp Ther 1995, 273:855-862.
33. Ott CE, Haas JA, Cuche JL, Knox FG. Effect of increased peritubule protein concentration on proximal tubule reabsorption in the presence and absence of extracellular volume expansion. J Clin Invest 1975, 55:612-620. 10.1172/JCI107969, 301790, 1117068.
34. Levine JS, Koh JS, Triaca V, Lieberthal W. Lysophosphatidic acid: a novel growth and survival factor for renal proximal tubular cells. Am J Physiol 1997, 273:F575-585.
35. Dixon R, Brunskill NJ. Activation of mitogenic pathways by albumin in kidney proximal tubule epithelial cells: implications for the pathophysiology of proteinuric states. J Am Soc Nephrol 1999, 10:1487-1497.
36. Iglesias J, Abernethy VE, Wang Z, Lieberthal W, Koh JS, Levine JS. Albumin is a major serum survival factor for renal tubular cells and macrophages through scavenging of ROS. Am J Physiol 1999, 277:F711-722.
37. Romanelli RG, La Villa G, Barletta G, Vizzutti F, Lanini F, Arena U, Boddi V, Tarquini R, Pantaleo P, Gentilini P, Laffi G. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol 2006, 12:1403-1407.
38. Lee YJ, Han HJ. Albumin-stimulated DNA synthesis is mediated by Ca2+/PKC as well as EGF receptor-dependent p44/42 MAPK and NF-κB signal pathways in renal proximal tubule cells. Am J Physiol Renal Physiol 2008, 294:F534-541. 10.1152/ajprenal.00408.2007, 18160626.
39. Contreras AM, Ramírez M, Cueva L, Alvarez S, de Loza R, Gamba G. Low serum albumin and the increased risk of amikacin nephrotoxicity. Rev Invest Clin 1994, 46:37-43.
40. Pockaj BA, Yang JC, Lotze MT, Lange JR, Spencer WF, Steinberg SM, Topalian SL, Schwartzentruber DJ, White DE, Rosenberg SA. A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapy. J Immunother Emphasis Tumor Immunol 1994, 15:22-28. 10.1097/00002371-199401000-00003, 8110727.
41. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, Berger ED, Lauchart W, Peszynski P, Freytag J, Hickstein H, Loock J, Löhr J-M, Liebe S, Emmrich J, Korten G, Schmidt R. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000, 6:277-286. 10.1053/lv.2000.6355, 10827226.
42. Wratten ML, Sereni L, Tetta C. Oxidation of albumin is enhanced in the presence of uremic toxins. Ren Fail 2001, 23:563-571. 10.1081/JDI-100104738, 11499570.
43. Stocker R, Glazer AN, Ames BN. Antioxidant activity of albumin-bound bilirubin. Proc Natl Acad Sci USA 1987, 84:5918-5922. 10.1073/pnas.84.16.5918, 298974, 3475708.
44. Quinlan GJ, Mumby S, Martin GS, Bernard GR, Gutteridge JM, Evans TW. Albumin influences total plasma antioxidant capacity favorably in patients with acute lung injury. Crit Care Med 2004, 32:755-759. 10.1097/01.CCM.0000114574.18641.5D, 15090958.
45. Wiedermann CJ, Wiedermann W, Joannidis M. Hypoalbuminemia and acute kidney injury: a meta-analysis of observational clinical studies. Intensive Care Med 2010, 36:1657-1665. 10.1007/s00134-010-1928-z, 20517593.
46. Choudhury D, Ahmed Z. Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol 2006, 2:80-91. 10.1038/ncpneph0076, 16932399.
47. Lukasewitz P, Kroh U, Löwenstein O, Krämer M, Lennartz H. Quantitative investigations of tissue accumulation of intermediate molecular weight hydroxyethyl starch in patients with multiple organ failure. J Anaesth Intensivbeh 1998, 3:42-46.
48. Dickenmann M, Oettl T, Mihatsch MJ. Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am J Kidney Dis 2008, 51:491-503. 10.1053/j.ajkd.2007.10.044, 18295066.
49. de Labarthe A, Jacobs F, Blot F, Glotz D. Acute renal failure secondary to hydroxyethylstarch administration in a surgical patient. Am J Med 2001, 111:417-418. 10.1016/S0002-9343(01)00873-7, 11599525.
50. Peron S, Mouthon L, Guettier C, Brechignac S, Cohen P, Guillevin L. Hydroxyethyl starch-induced renal insufficiency after plasma exchange in a patient with polymyositis and liver cirrhosis. Clin Nephrol 2001, 55:408-411.
51. Ebcioglu Z, Cohen DJ, Crew RJ, Hardy MA, Ratner LE, D'Agati VD, Markowitz GS. Osmotic nephrosis in a renal transplant recipient. Kidney Int 2006, 70:1873-1876. 10.1038/sj.ki.5001737, 16883320.
52. Hagne C, Schwarz A, Gaspert A, Giambarba C, Keusch G. HAES in septic shock - sword of Damocles?. Schweiz Med Forum 2009, 9:304-306.
53. Pillebout E, Nochy D, Hill G, Conti F, Antoine C, Calmus Y, Glotz D. Renal histopathological lesions after orthotopic liver transplantation (OLT). Am J Transplant 2005, 5:1120-1129. 10.1111/j.1600-6143.2005.00852.x, 15816895.
54. Lamke LO, Liljedahl SO. Plasma volume changes after infusion of various plasma expanders. Resuscitation 1976, 5:93-102. 10.1016/0300-9572(76)90029-0, 69313.
55. Nagy KK, Davis J, Duda J, Fildes J, Roberts R, Barrett J. A comparison of pentastarch and lactated Ringer's solution in the resuscitation of patients with hemorrhagic shock. Circ Shock 1993, 40:289-294.
56. Degrémont AC, Ismaïl M, Arthaud M, Oulare B, Mundler O, Paris M, Baron JF. Mechanisms of postoperative prolonged plasma volume expansion with low molecular weight hydroxethyl starch (HES 200/0.62, 6%). Intensive Care Med 1995, 21:577-583. 10.1007/BF01700163, 7593900.
57. Rock G, Sutton DM, Freedman J, Nair RC. Pentastarch instead of albumin as replacement fluid for therapeutic plasma exchange. The Canadian Apheresis Group. J Clin Apheresis 1997, 12:165-169. 10.1002/(SICI)1098-1101(1997)12:4<165::AID-JCA2>3.0.CO;2-8, 9483177.
58. Goss GA, Weinstein R. Pentastarch as partial replacement fluid for therapeutic plasma exchange: effect on plasma proteins, adverse events during treatment, and serum ionized calcium. J Clin Apheresis 1999, 14:114-121. 10.1002/(SICI)1098-1101(1999)14:3<114::AID-JCA2>3.0.CO;2-8, 10540365.
59. Boldt J, Brosch C, Röhm K, Lehmann A, Mengistu A, Suttner S. Is albumin administration in hypoalbuminemic elderly cardiac surgery patients of benefit with regard to inflammation, endothelial activation, and long-term kidney function?. Anesth Analg 2008, 107:1496-1503. 10.1213/ane.0b013e31818370b2, 18931204.
60. Hüter L, Simon TP, Weinmann L, Schuerholz T, Reinhart K, Wolf G, Amann KU, Marx G. Hydroxyethylstarch impairs renal function and induces interstitial proliferation, macrophage infiltration and tubular damage in an isolated renal perfusion model. Crit Care 2009, 13:R23. 10.1186/cc7726, 2688141, 19239718.